Interfaces
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


INTERFACES
Vol. 37, No. 1, January-February 2007, pp. 22-38
DOI: 10.1287/inte.1060.0275
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cox, L. A.
Right arrow Articles by Carnevale, R.
Right arrow Search for Related Content

Quantifying Human Health Risks from Animal Antimicrobials

Louis Anthony (Tony) Cox, Jr., Douglas A. Popken, Richard Carnevale

Cox Associates, 503 Franklin Street, Denver, Colorado 80218
Cox Associates, 503 Franklin Street, Denver, Colorado 80218
Animal Health Institute, 1325 G Street NW, Suite 700, Washington, DC 20005-3104

tony{at}cox-associates.com
doug{at}cox-associates.com
rcarnevale{at}ahi.org

In 1969, the Joint Committee on the Use of Antibiotics in Animal Husbandry and Veterinary Medicine in the United Kingdom warned that uncontrolled use of similar antimicrobials in humans and food animals might promote the emergence of resistant strains of foodborne bacteria that could endanger human health and compromise the effectiveness of antimicrobial therapies in human patients (Swann 1969). The Animal Health Institute (AHI) and its member companies collaborated with Cox Associates, an operations research consulting company, to develop and apply new, practical, quantitative risk assessment (QRA) modeling methods to assess the previously impossible-to-quantify risks (and benefits) to human health from continued use of animal antimicrobials. We came to some surprising conclusions that were robust to many uncertainties. Among these were that antimicrobials that benefit animal health may benefit human health, while regulatory interventions that seek to reduce antimicrobial resistance in animals may unintentionally increase illness rates (and hence antimicrobial use and resistance rates) in humans. These new QRA models and methods enable industry and regulatory decision makers to quantify and compare the probable human health consequences of alternative animal antimicrobial use plans and to design more effective approaches to protect human and animal health.

Key Words: decision analysis; risk; health care; epidemiology






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by INFORMS.